News ID: 271630
Published: 0351 GMT July 17, 2020

Iran to export anti-coronavirus medicine to Kyrgyzstan

Iran to export anti-coronavirus medicine to Kyrgyzstan

Kyrgyz Prime Minister Kubatbek Ayilchiyevich Boronov said the Central Asian country plans to import medicine from Iran to fight against the coronavirus and pneumonia.

 

Kyrgyz experts are to make a trip to Tehran in this regard, Fars News Agency quoted him saying.

Based on the negotiations with Tehran, this week a special flight will transport Kyrgyzstan's required medicine from Tehran to cure COVID-19 and pneumonia, Boronov said.

Bishkek is reportedly holding similar talks with Russia, India, Uzbekistan and Pakistan.

Iran announced that domestically-made Remdesivir will go on sale in country’s market in coming days, as the country’s research and scientific centers continue broad studies to find an ultimate remedy and vaccine against the virus causing deadly COVID-19.

Iran will distribute the first batch of Remdesivir medicine to the local market to treat coronavirus patients next week, Iranian Health Minister Saeed Namaki announced on Wednesday.

“No reliable drug has yet been found for the COVID-19 disease in the world but Remdesivir and Favipiravir are two drugs that a number of our colleagues prescribe, specially Remdesivir whose effectiveness has been emphasized in the US and Europe,” Namaki told reporters after a cabinet meeting in Tehran.

He said that Iran provided the medical centers and pharmacies with enough Remdesivir on Tuesday, adding that the Iran-made version of the drug will be distributed in the market next week.

Favipiravir was developed by the Japanese company Fujifilm Toyama Chemical in 2014 and used for treatment of new strains of influenza.

The US Food and Drug Administration (FDA) has authorized emergency use of the Ebola drug Remdesivir for treating the coronavirus. A recent clinical trial showed the drug helped shorten the recovery time for people who were seriously ill; however, it did not significantly improve survival rates.

   
KeyWords
 
Comments
Comment
Name:
Email:
Comment:
Security Key:
Captcha refresh
Page Generated in 3/1863 sec